Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 30 | 2026EASD 2026 Key Press Releases (September 30 Part 2)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 30 | 2026TRIUMPH-5 is All TriumphPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 30 | 2026EASD 2026 Key Press Releases (September 30)Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 29 | 2026EASD 2026 Key Press Releases (September 29)Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 28 | 2026EASD 2026 Key Press Releases (September 28)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 27 | 2026Negative Nancy: Novo 2026 Capital Markets Day Highlights and Analysis Part 3Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Sep 25 | 2026EASD 2026 Preview: Where FENIX will be paying attention and whyPurchase Blast
$599
Posted in: Other, Topics Sep 25 | 2026Novo Partners for Q3M AOMs; Clywedog Announces Ph1b T2DM DataPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, Topics Sep 25 | 2026Onswik FDA Approval; Lilly Medicare GLP-1 Bridge Program Market Share; BI + WHO Global Metabolic Health Collaboration; Roche + Atavistik Partner for Allosteric Drug Discovery; Aqua Medical T2DM Endoscopic Procedure; Biolinq Shine OTC FDA Clearance; Rezera RESOLVE-1 AHA PresentationPurchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics Sep 23 | 2026Wave Ph2 WVE-007 + Tirzepatide Combination Study; Abbott Partners with Berry Street for Nutrition Insights with LingoPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 22 | 2026Viking Pops 31% on Maintenance Data; Roche Ph2 Enicepatide Results; New Lilly Manufacturing Facility; Obi Approved in the EU; Petrelintide Ph3 ProgramPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 22 | 2026Positive Pants Part 2: Novo 2026 Capital Markets Day Highlights and AnalysisPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 22 | 2026Positive Pants Part 1: Novo 2026 Capital Markets Day Highlights and AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 18 | 2026Novo Initiates Zenagamtide CVOT in Obesity; Novo Enters Purchase Agreement for Three Obesity Programs with Kallyope; Health Canada Approves Sandoz Generic SemaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 18 | 2026Obesity Spotlight Series: Emerging Players to WatchPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 17 | 2026Novo Partners for Oral Drug Discovery; Bayer’s Kerendia Receives T1DM FDA Label Expansion; AbbVie’s Allergan Skincare + AOM Data; Roche Opens Boston CVRM Innovation CenterPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Sep 16 | 2026Pfizer Initiates Ph3 Berobenatide OSA Study; Novo Ph3 Zenagamtide Study in Japan; Novo and Anthropic Partner for Drug and AI DevelopmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Sep 15 | 2026Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in IndiaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 14 | 2026Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP AgendaPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Sep 11 | 2026Novo to Announce Org Changes; Novartis/Ionis Pelacarsen UpdatesPurchase Blast